open access

Vol 10, Supp. A (2019)
Case report
Published online: 2019-04-26
Get Citation

Ruxolitinib treatment in a patient with primary myelofibrosis and thrombocytopenia

Paweł Chrząstek1, Dariusz Woszczyk1
DOI: 10.5603/Hem.2019.0009
Affiliations
  1. Oddział Kliniczny Chorób Wewnętrznych i Hematologii, Uniwersytet Opolski, Szpital Wojewódzki w Opolu, ul. Katowicka 64, 45–001 Opole, Poland

open access

Vol 10, Supp. A (2019)
CASE REPORTS
Published online: 2019-04-26

Abstract

46-years old male diagnosed with primary myelofibrosis (PMF) was included into therapeutic program of treatment with ruxolitinib. Due to initial thrombocytopenia with basal platelets [PLT] range below 100 G/l, initial dosage of the treatment was reduced according to characteristics of drug. No treatment-related toxicity was noted, the dosage was gradually increased reaching the dose 20 mg twice a day at twelfth week of therapy. Although alleviation of systemic symptoms was reached, lack of diminishment of spleen size demanded by therapeutic program led to cessation of treatment. In group of patients with PMF and secondary thrombocytopenia treatment with ruxolitinib may lead to improvement of patient condition.

Abstract

46-years old male diagnosed with primary myelofibrosis (PMF) was included into therapeutic program of treatment with ruxolitinib. Due to initial thrombocytopenia with basal platelets [PLT] range below 100 G/l, initial dosage of the treatment was reduced according to characteristics of drug. No treatment-related toxicity was noted, the dosage was gradually increased reaching the dose 20 mg twice a day at twelfth week of therapy. Although alleviation of systemic symptoms was reached, lack of diminishment of spleen size demanded by therapeutic program led to cessation of treatment. In group of patients with PMF and secondary thrombocytopenia treatment with ruxolitinib may lead to improvement of patient condition.
Get Citation

Keywords

primary myelofibrosis, myelofibrosis, thrombocytopenia, ruxolitinib

About this article
Title

Ruxolitinib treatment in a patient with primary myelofibrosis and thrombocytopenia

Journal

Hematology in Clinical Practice

Issue

Vol 10, Supp. A (2019)

Article type

Case report

Pages

8-12

Published online

2019-04-26

DOI

10.5603/Hem.2019.0009

Keywords

primary myelofibrosis
myelofibrosis
thrombocytopenia
ruxolitinib

Authors

Paweł Chrząstek
Dariusz Woszczyk

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.